Bayer Devoting $350 Mil. For OTC Line Extensions, New Indications
This article was originally published in The Tan Sheet
Executive Summary
Bayer Worldwide Consumer Care plans to invest $350 mil. on R&D over the next five years, Consumer Care Division President Gary Balkema reported in a March 30 teleconference discussing the company's 1998 results. The company will focus on cultivating line extensions and new indications for existing products.